# EDGAR Filing Document

**Accession Number:** 0001128189
**File Stem:** 0001079973-25-001802
**Filing Date:** 2025-11
**Character Count:** 6633
**Document Hash:** cee6ba8f91305d053c099e35505e203d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001079973-25-001802.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001079973-25-001802

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251113

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ProtoKinetix, Inc.
- **CENTRAL INDEX KEY:** 0001128189
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943355026
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-32917
- **FILM NUMBER:** 251500244

**BUSINESS ADDRESS:**
- **STREET 1:** 109 W. MAIN ST.
- **CITY:** DALTON
- **STATE:** OH
- **ZIP:** 44618
- **BUSINESS PHONE:** 330-445-4971

**MAIL ADDRESS:**
- **STREET 1:** 109 W. MAIN ST.
- **CITY:** DALTON
- **STATE:** OH
- **ZIP:** 44618

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RJV NETWORK INC
- **DATE OF NAME CHANGE:** 20010130

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report: **November 13, 2025**

**<u>ProtoKinetix, Incorporated</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **<u>Nevada</u>** | **<u>000-32917</u>** | **<u>94-3355026</u>** |
| State of Incorporation | Commission<br> File Number | IRS Employer<br> Identification Number |

---

**109 W Main Street, <u>Dalton, OH 44618</u>**

Address of principal executive offices

**<u>330-445-4971</u>**

Telephone number, including Area Code

_______________________________

Former name or former address if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| N/A |  |  |

---

**Item 7.01. Regulation FD Disclosure.**

This Current Report on Form 8-K/A (this "Amendment") amends that certain Current Report on Form 8-K filed by ProtoKinetix, Incorporated (the "Company") with the Securities and Exchange Commission on November 17, 2025 (the "Original Filing"). The sole purpose of this Amendment is to correct the contact number for the Company included in the Original Filing and include a revised copy of the press release posted on the Company's website on November 17, 2025. The full text of the press release referenced herein is furnished hereto as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 7.01 of the Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

**Item 9.01. Financial Statements and Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| 99.1 | [Press release dated November 17, 2025](ex99x1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

 

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 19th day of November 2025.

---

| | |
|:---|:---|
| **ProtoKinetix, Inc.** | **ProtoKinetix, Inc.** |
| By: | /s/ Michael Guzzetta |
|  | Michael Guzzetta, President, CEO & CFO |

---

## Exhibit 99.1

Exhibit 99.1

![](image_026.jpg)

**ProtoKinetix Incorporated Mourns the Loss of President and Chief Executive Officer Clarence E. Smith; Appointment of Michael Guzzetta as His Successor**

Dalton, OH, November 17, 2025. ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTC: PKTX), a clinical-stage biomedical company, today deeply regrets to announce our President and Chief Executive Officer Clarence E. Smith, died in a tragic accident on November 13, 2025.

Mr. Smith was appointed President and Chief Executive Officer for the Company on February 19, 2015 and was previously appointed a member of the Board of Directors of the Company on June 1, 2014 and served in those roles until his untimely death.

Michael Guzzetta, the Company's Chief Financial Officer, commented, "Clarence always had a positive outlook. He was a truly engaging personality and the driving force behind our Company. On behalf of his friends and colleagues at Protokinetix, we wish to extend our deepest condolences to his family and friends."

On November 16, 2025, the Company's sole remaining director, Ed McDonough, appointed Mr. Guzzetta as Chairman of the Board of Directors, President, and Chief Executive Officer, to serve until his successor is duly elected and qualified. Mr. Guzzetta will continue to serve as the Company's Chief Financial Officer, Secretary and Treasurer.

About ProtoKinetix, Incorporated

For further information, please contact:

**Michael Guzzetta**

*President, CEO & CFO*

Telephone: 330-445-4971

Email: mguzzetta@protokinetix.com